🔥 Trade Alert 🔥 BNOX

BNOX upside potential is over a staggering 700%!  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ BNOX may be on the way to generating TRIPLE DIGIT returns! Greetings Investors, The world may be recovering from the pandemic, but the need for medicine will never go away. The biotech arena is here to stay, and it gives investors an opportunity to grow their portfolios all while supporting an industry that fulfills needs. The industry is ripe with large-cap biotech stocks whose market capitalizations are in the upper billions. These companies have products on the market and treat different medical conditions. The growth potential is there, but at what speed? This sheds light on the small-cap biotech space where despite their lower market capitalizations, the companies have ample room for accelerated growth. With that said, get your eyes on Bionomics Limited (Nasdaq: BNOX), which trades at just a little over $1.00. BNOX may be at a supreme value right now as the stock has just hit a 52-week low. This clinical-stage biotechnology company is developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical needs. BNOX currently has a “STRONG BUY” at [NASDAQ.com](~/AASl5QA~/RgRm20oDP0SPaHR0cHM6Ly93d3cubmFzZGFxLmNvbS9tYXJrZXQtYWN0aXZpdHkvc3RvY2tzL2Jub3gvYW5hbHlzdC1yZXNlYXJjaD9fa3g9Xy1IU3BvMnk5bERXSmU1Zks2eDM2V2NwZU1iMEV6c1pmSXZmU1N2dEFMdDd5cDVfbzM3d05vSU16TlQwbDJEWC5UYTlyaExXA3NwY0IKZPADxfhkvFkHm1IbdHJpc3RyYW1iYWxkd2luODhAZ21haWwuY29tWAQABeGx) along with several notable analysts BULLISH on the company. Based on analysts offering 12-month price targets for BNOX in the last 3 months, the average price target is $7! This is roughly 7x higher than current levels! A market cap of nearly $10M, plenty of strategic moves from management, and a promising pipeline indicate that this underfollowed biotech company could be ripe for a massive bounce and explosive gains! [www.bionomics.com.au](~/AASl5QA~/RgRm20oDP0TlaHR0cHM6Ly93d3cuZ2xvYmVuZXdzd2lyZS5jb20vVHJhY2tlcj9kYXRhPXN6a0VnQmlJTTN5TW96T0JUVmF1eFFGcS15cGdISFIwM2lSQkIzenAxMFM1SUh6dDAza0NtRE92NTEwOGpvaWJFc3doRndWQWlvU1V4c3M3TTlzOGVPTGxjT2VqeVJzdk9OelM4UFEwUkZNJTNEJl9reD1fLUhTcG8yeTlsRFdKZTVmSzZ4MzZXY3BlTWIwRXpzWmZJdmZTU3Z0QUx0N3lwNV9vMzd3Tm9JTXpOVDBsMkRYLlRhOXJoTFcDc3BjQgpk8APF-GS8WQebUht0cmlzdHJhbWJhbGR3aW44OEBnbWFpbC5jb21YBAAF4bE~) Company Overview: BNOX is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Utilizing the company’s deep expertise in ion channel biology and translational medicine, it designs best-in-class oral, small molecules to modulate ion channel function, influence neurotransmission and consequently downstream signaling in the brain. The company is currently focused on its proprietary allosteric modulators. Negative allosteric modulators (“NAMs”) of the α7 receptor are developed for the treatment of anxiety and stressor related disorders and Positive allosteric modulators (“PAMs”) are developed for the treatment of cognitive dysfunction. Focused CNS Pipeline Bionomics has a CNS-focused pipeline led by its programs in Social Anxiety Disorder (“SAD”) and Post-Traumatic Stress Disorder (“PTSD”), both of which received the U.S Food and Drug Administration (FDA) Fast Track Designation! About Social Anxiety Disorder: SAD is a significant and persistent fear of social and performance-related situations. One of the most common mental disorders in the United States, an estimated 31 million Americans will suffer from SAD at some point in their lives. SAD can interfere with a person’s ability to work, make it difficult to maintain friendships, family relationships, and romantic partnerships, cause a person to avoid lifestyle activities like dining out and traveling, and make normal parts of everyday life such as grocery shopping, calling a handyman, or picking up coffee challenging. Fifteen million, or seven percent, of American adults have Social Anxiety Disorder. More than 75% of people experience their first symptoms during their childhood or early teenage years. People with social anxiety disorder are also at an increased risk for substance use disorder and major depressive disorder. ([SOURCE](~/AASl5QA~/RgRm20oDP0TuaHR0cHM6Ly93d3cubWhhbmF0aW9uYWwub3JnL2NvbmRpdGlvbnMvc29jaWFsLWFueGlldHktZGlzb3JkZXI_X2t4PV8tSFNwbzJ5OWxEV0plNWZLNngzNldjcGVNYjBFenNaZkl2ZlNTdnRBTHQ3eXA1X28zN3dOb0lNek5UMGwyRFguVGE5cmhMIzp-OnRleHQ9RmlmdGVlbiUyMG1pbGxpb24lMkMlMjBvciUyMHNldmVuJTIwcGVyY2VudCxkaXNvcmRlciUyMGFuZCUyMG1ham9yJTIwZGVwcmVzc2l2ZSUyMGRpc29yZGVyLlcDc3BjQgpk8APF-GS8WQebUht0cmlzdHJhbWJhbGR3aW44OEBnbWFpbC5jb21YBAAF4bE~)) About PTSD: Post-traumatic stress disorder (PTSD) is a disorder that develops in some people who have experienced a shocking, scary, or dangerous event. It is natural to feel afraid during and after a traumatic situation. Fear triggers many split-second changes in the body to help defend against danger or to avoid it. About 5 out of every 100 adults (or 5%) in the U.S. has PTSD in any given year. In 2020, about 13 million Americans had PTSD. Women are more likely to develop PTSD than men. About 8 of every 100 women (or 8%) and 4 of every 100 men (or 4%) will have PTSD at some point in their life. ([SOURCE](~/AASl5QA~/RgRm20oDP0TOaHR0cHM6Ly93d3cucHRzZC52YS5nb3YvdW5kZXJzdGFuZC9jb21tb24vY29tbW9uX2FkdWx0cy5hc3A_X2t4PV8tSFNwbzJ5OWxEV0plNWZLNngzNldjcGVNYjBFenNaZkl2ZlNTdnRBTHQ3eXA1X28zN3dOb0lNek5UMGwyRFguVGE5cmhMIzp-OnRleHQ9QWJvdXQlMjA1JTIwb3V0JTIwb2YlMjBldmVyeSxzb21lJTIwcG9pbnQlMjBpbiUyMHRoZWlyJTIwbGlmZS5XA3NwY0IKZPADxfhkvFkHm1IbdHJpc3RyYW1iYWxkd2luODhAZ21haWwuY29tWAQABeGx)) Partnership with Merck: Beyond BNC210, BNOX also has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions. Merck α7 receptor PAM Collaboration - In June 2014 Bionomics entered into in 2014 to develop α7 receptor PAMs targeting cognitive dysfunction associated with Alzheimer’s disease and other central nervous system conditions - Merck funds all R&D activities including clinical development and worldwide commercialization of any products from collaboration - Payments received: US$20M upfront and US$10M for Phase 1 milestone - Eligible to receive up to US$465M in additional milestone payments plus royalties BNOX’s pipeline additionally includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels being developed for CNS conditions of high unmet need. Other Partnerships: In 2021 Bionomics entered into a Memorandum of Understanding with EmpathBio, which sets out an initial collaborative framework of preclinical studies to collectively explore a combination drug treatment regimen with BNC210 and EMP-01 (3,4 Methylenedioxymethamphetamine (MDMA) derivative). MDMA-assisted psychotherapy has demonstrated significant symptom improvement in PTSD patients and FDA has granted a Breakthrough Therapy designation to MDMA-assisted psychotherapy. Empath Bio is developing MDMA derivatives that may permit the entactogenic effects of MDMA to be separated from some of the known adverse effects. Exclusive BNC101 Oncology License Agreement for the Development of CAR-T Therapeutics In 2020 Bionomics announced that it has entered into an exclusive Agreement to license Bionomics’ BNC101 oncology drug candidate to Carina Biotech (Carina), for the development of Chimeric Antigen Receptor T cell (CAR-T) therapy, which harnesses the body’s immune system to fight cancer. Under the worldwide, exclusive License Agreement, Carina will fund all research and development activities. Bionomics is eligible to receive up to A$118 million in clinical & development milestones plus royalty payments if Carina fully develops and markets the new therapy. In the event that Carina sub-licenses the CAR-T treatment, Bionomics is eligible to share in the sub-licensing revenues in early clinical development and receive a substantial double-digit portion of the revenues in later stages of clinical development. What are the immediate reasons for having BNOX at the top of your radar right now? An FDA meeting is around the corner…. The company is currently preparing for a U.S. Food and Drug Administration (FDA) End of Phase 2 (EoPh2) meeting to discuss the registrational program for BNC210 in SAD. The meeting is planned for mid-September 2023. Start-up activities for a planned Phase 3 trial of BNC210 in SAD are underway. Contingent upon advice received by the FDA, the company is planning to initiate dosing in the Phase 3 study in SAD during the Quarter ending 31 March 2024. In addition, the company continued over-seeing its recurring Independent Safety Review Committee meetings in the ongoing Phase 2b ATTUNE study of BNC210 in PTSD which completed enrollment and remains on track for topline data readout expected by the end of September. Plenty of cash on hand… BNOX has plenty of cash on hand to fund its endeavors. The Company’s cash balance on 30 June 2023 was $18.25 million. Strategic updates to leadership… 2023 has been a busy year with key leadership updates that drive BNOX’s U.S. focused transformation and next stage of strategic growth. Alan Fisher has been appointed Non-Executive Chair of the Board while Tim Cunningham of Danforth Associates has been appointed Chief Financial Officer. BNOX has also appointed Julie Kerner, Ph.D., as Senior Vice President of Business Operations, and Atul R. Mahableshwarkar, M.D., as the Acting Chief Medical Officer. Additionally, the company has engaged Francisco Bejar as a strategic advisor to head the business development efforts in the U.S. and abroad. “With the addition of multiple U.S.-based and highly accomplished industry executives, we believe we have positioned Bionomics for sustainable growth as we continue to advance our corporate evolution. Collectively, Tim, Julie, and Atul bring over 50+ years of experience in the biopharma sector, and diverse expertise in developing and commercializing drug products. I am confident that their complementary skill sets will be instrumental in leading the Company into a new era focused on the fiscally efficient advancement of our late-stage programs.” -- Spyros Papapetropoulos, M.D., Ph.D., President and CEO of BNOX In summary…. Two common conditions in mental health are social anxiety disorder (SAD) and post-traumatic stress disorder (PTSD). BNOX is addressing both! BNOX could be seeing Breakthrough Therapy designation for PTSD in its future, which is extremely noteworthy as no new therapy has been approved in about 20 years for PTSD. With an FDA meeting around the corner, now is the time to keep a good eye on news/developments! The exhaustion of selling pressure coupled with a hefty price target of $7 on the stock could serve as catalysts for a major trend reversal soon for BNOX. Start your research right away! Copyright 2023 © SCDalerts.com is owned and operated by the owner of SCD Media LLC. Disclaimer and Privacy For more Information please contact info@smallcapsdaily.com This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. SCD Media, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to SCD Alerts. SCD Alerts is a financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by SCD Media. Any wording found in this e-mail or disclaimer referencing “I” or “we” or “our” or “SCD” refers to SCD Media. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in BNOX. We have been currently compensated up to Fifteen Thousand Dollars Cash ($15,000) via bank wire transfer from a third-party IA Media, LLC for a 1 Day Marketing Program regarding BNOX with a start date of 9/06/2023. SCD’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non- compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, SCD often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. Small Caps Daily 1334 Northampton St Easton, PA 18042 © 2023 | All rights reserved. [Unsubscribe](~/AASl5QA~/RgRm20oDP0SpaHR0cHM6Ly9tYW5hZ2Uua21haWwtbGlzdHMuY29tL3N1YnNjcmlwdGlvbnMvdW5zdWJzY3JpYmU_YT1UYTlyaEwmYz0wMUdBUDRURE0xUkE3R1FXWDRXNUZONUpCViZrPTFhOTc5MjY1ZGNmNjg1M2Y1ZmJhOWM4OWMyYmYxYmMyJm09MDFIOU5WU1I3V1JKR0QwUzI0WTZXTTg4WFEmcj0zMjZxYUxqUVcDc3BjQgpk8APF-GS8WQebUht0cmlzdHJhbWJhbGR3aW44OEBnbWFpbC5jb21YBAAF4bE~). [Twitter] [Facebook] [Instagram]